The University of Queensland

Response to Comment on “Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice”

Albornoz, Eduardo A., Gordon, Richard, Kumar, Vinod, Robertson, Avril A. B., Schroder, Kate and Woodruff, Trent M. (2023). Response to Comment on “Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice”. Science Translational Medicine, 15 (696) adh0604. doi: 10.1126/scitranslmed.adh0604

Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection

Sikder, Md. Al Amin, Rashid, Ridwan B., Ahmed, Tufael, Sebina, Ismail, Howard, Daniel R., Ullah, Md. Ashik, Rahman, Muhammed Mahfuzur, Lynch, Jason P., Curren, Bodie, Werder, Rhiannon B., Simpson, Jennifer, Bissell, Alec, Morrison, Mark, Walpole, Carina, Radford, Kristen J., Kumar, Vinod, Woodruff, Trent M., Ying, Tan Hui, Ali, Ayesha, Kaiko, Gerard E., Upham, John W., Hoelzle, Robert D., Cuív, Páraic Ó., Holt, Patrick G., Dennis, Paul G. and Phipps, Simon (2023). Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection. Immunity, 56 (5), 1098-1114.e10. doi: 10.1016/j.immuni.2023.03.002

Vitamin B12 deficiency induces glucose intolerance, delays peak insulin levels and promotes ketogenesis in female rats

Neal, Elliott, Kumar, Vinod, Borges, Karin and Cuffe, James S.M. (2023). Vitamin B12 deficiency induces glucose intolerance, delays peak insulin levels and promotes ketogenesis in female rats. The Journal of Endocrinology, 256 (2) e220158, 1-16. doi: 10.1530/joe-22-0158

Success in navigating hurdles to oral delivery of a bioactive peptide complement antagonist through use of nanoparticles to increase bioavailability and in vivo efficacy

Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria X., Whittaker, Andrew K., Xu, Zhi Ping, Smith, Maree T., Woodruff, Trent M. and Han, Felicity Y (2022). Success in navigating hurdles to oral delivery of a bioactive peptide complement antagonist through use of nanoparticles to increase bioavailability and in vivo efficacy. Advanced Therapeutics, 5 (12) 2200109, 2200109. doi: 10.1002/adtp.202200109

Prenatal choline supplementation alters one carbon metabolites in a rat model of periconceptional alcohol exposure

Steane, Sarah E., Kumar, Vinod, Cuffe, James S. M., Moritz, Karen M. and Akison, Lisa K. (2022). Prenatal choline supplementation alters one carbon metabolites in a rat model of periconceptional alcohol exposure. Nutrients, 14 (9) 1874. doi: 10.3390/nu14091874

Reduced Growth, Altered Gut Microbiome and Metabolite Profile, and Increased Chronic Kidney Disease Risk in Young Pigs Consuming a Diet Containing Highly Resistant Protein

Murray, Margaret, Coughlan, Melinda T., Gibbon, Anne, Kumar, Vinod, Marques, Francine Z., Selby-Pham, Sophie, Snelson, Matthew, Tsyganov, Kirill, Williamson, Gary, Woodruff, Trent M., Wu, Tong and Bennett, Louise E. (2022). Reduced Growth, Altered Gut Microbiome and Metabolite Profile, and Increased Chronic Kidney Disease Risk in Young Pigs Consuming a Diet Containing Highly Resistant Protein. Frontiers in Nutrition, 9 816749, 816749. doi: 10.3389/fnut.2022.816749

In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy

Cui, Cedric S., Kumar, Vinod, Gorman, Declan M., Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy. ACS Pharmacology and Translational Science, 5 (1) acsptsci.1c00227, 41-51. doi: 10.1021/acsptsci.1c00227

Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice

Xu, Weizhi, Maqbool, Faheem, Kumar, Vinod, Falconer, James R., Cui, Cedric S., Woodruff, Trent M., Borges, Karin, Whittaker, Andrew K., Smith, Maree T. and Han, Felicity Y. (2021). Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Delivery and Translational Research, 12 (10), 2518-2526. doi: 10.1007/s13346-021-01093-3

Optimisation of a microfluidic method for the delivery of a small peptide

Han, Felicity Y., Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria, Jiang, Xingyu, Woodruff, Trent M., Whittaker, Andrew K. and Smith, Maree T. (2021). Optimisation of a microfluidic method for the delivery of a small peptide. Pharmaceutics, 13 (9) 1505, 1505. doi: 10.3390/pharmaceutics13091505

Glucose clearance and uptake is increased in the SOD1 G93A mouse model of amyotrophic lateral sclerosis through an insulin‐independent mechanism

McDonald, Tanya S., Kumar, Vinod, Fung, Jenny N., Woodruff, Trent M. and Lee, John D. (2021). Glucose clearance and uptake is increased in the SOD1 G93A mouse model of amyotrophic lateral sclerosis through an insulin‐independent mechanism. The FASEB Journal, 35 (7) e21707, e21707. doi: 10.1096/fj.202002450r

The “C3aR Antagonist” SB290157 is a partial C5aR2 agonist

Li, Xaria X., Kumar, Vinod, Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). The “C3aR Antagonist” SB290157 is a partial C5aR2 agonist. Frontiers in Pharmacology, 11 591398, 591398. doi: 10.3389/fphar.2020.591398

A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models

Kumar, Vinod, Lee, John D., Coulson, Elizabeth J. and Woodruff, Trent M. (2020). A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. Journal of Neurochemistry, 158 (3) jnc.15119, 807-817. doi: 10.1111/jnc.15119

Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation

Han, Felicity Y., Liu, Yun, Kumar, Vinod, Xu, Weizhi, Yang, Guangze, Zhao, Chun-Xia, Woodruff, Trent M., Whittaker, Andrew K. and Smith, Maree T. (2020). Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. International Journal of Pharmaceutics, 581 119291, 119291. doi: 10.1016/j.ijpharm.2020.119291

Low-fouling fluoropolymers for bioconjugation and in vivo tracking

Fu, Changkui, Demir, Baris, Alcantara, Sheilajen, Kumar, Vinod, Han, Felicity, Kelly, Hannah, Tan, Xiao, Yu, Ye, Xu, Weizhi, Zhao, Jiacheng, Zhang, Cheng, Peng, Hui, Boyer, Cyrille, Woodruff, Trent, Kent, Stephen, Searles, Debra and Whittaker, Andrew (2020). Low-fouling fluoropolymers for bioconjugation and in vivo tracking. Angewandte Chemie International Edition, 59 (12), 4729-4735. doi: 10.1002/anie.201914119

Low‐fouling fluoropolymers for bioconjugation and in vivo tracking

Fu, Changkui, Demir, Baris, Alcantara, Sheilajen, Kumar, Vinod, Han, Felicity, Kelly, Hannah G., Tan, Xiao, Yu, Ye, Xu, Weizhi, Zhao, Jiacheng, Zhang, Cheng, Peng, Hui, Boyer, Cyrille, Woodruff, Trent M., Kent, Stephen J., Searles, Debra J. and Whittaker, Andrew K. (2020). Low‐fouling fluoropolymers for bioconjugation and in vivo tracking. Angewandte Chemie, 132 (12), 4759-4765. doi: 10.1002/ange.201914119

Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice

Kumar, Vinod, Lee, John D., Clark, Richard J., Noakes, Peter G., Taylor, Stephen M. and Woodruff, Trent M. (2020). Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice. ACS Omega, 5 (5) acsomega.9b03735, 2345-2354. doi: 10.1021/acsomega.9b03735

Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility

Tan, Sih Min, Ziemann, Mark, Thallas-Bonke, Vicki, Snelson, Matthew, Kumar, Vinod, Laskowski, Adrienne, Nguyen, Tuong-Vi, Huynh, Kevin, Clarke, Michele V., Libianto, Renata, Baker, Scott T., Skene, Alison, Power, David A., MacIsaac, Richard J., Henstridge, Darren C., Wetsel, Rick A., El-Osta, Assam, Meikle, Peter J., Wilson, Scott G., Forbes, Josephine M., Cooper, Mark E., Ekinci, Elif I., Woodruff, Trent M. and Coughlan, Melinda T. (2019). Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility. Diabetes, 69 (1), 83-98. doi: 10.2337/db19-0043

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Gordon, Richard, Albornoz, Eduardo A., Christie, Daniel C., Langley, Monica R., Kumar, Vinod, Mantovani, Susanna, Robertson, Avril A. B., Butler, Mark S., Rowe, Dominic B., O'Neill, Luke A., Kanthasamy, Anumantha G., Schroder, Kate, Cooper, Matthew A. and Woodruff, Trent M. (2018). Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine, 10 (465) aah4066, eaah4066. doi: 10.1126/scitranslmed.aah4066

Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

Kumar, Vinod, Lee, John D., Clark, Richard J. and Woodruff, Trent M. (2018). Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. Scientific Reports, 8 (1) 8101, 8101. doi: 10.1038/s41598-018-26387-4

Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis

Michailidou, Iliana, Jongejan, Aldo, Vreijling, Jeroen P., Georgakopoulou, Theodosia, de Wissel, Marit B., Wolterman, Ruud A., Ruizendaal, Patrick, Klar-Mohamad, Ngaisah, Grootemaat, Anita E., Picavet, Daisy I., Kumar, Vinod, van Kooten, Cees, Woodruff, Trent M., Morgan, B. Paul, van der Wel, Nicole N., Ramaglia, Valeria, Fluiter, Kees and Baas, Frank (2018). Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 6 (1) 36, 36. doi: 10.1186/s40478-018-0536-y

Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis

Lee, John D., Kumar, Vinod, Fung, Jenny N. T., Ruitenberg, Marc J., Noakes, Peter G. and Woodruff, Trent M. (2017). Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 173 (8), 689-699. doi: 10.1111/bph.13730

Autoantibodies against homocysteinylated protein in a mouse model of folate deficiency-induced neural tube defects

Denny, Kerina J., Kelly, Christina F., Kumar, Vinod, Witham, Katey L., Cabrera, Robert M., Fennell, Richard H., Taylor, Stephen M., Jeanes, Angela and Woodruff, Trent M. (2016). Autoantibodies against homocysteinylated protein in a mouse model of folate deficiency-induced neural tube defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 106 (3), 201-207. doi: 10.1002/bdra.23483

Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice

Mantovani, Susanna, Gordon, Richard, Li, Rui, Christie, Daniel C., Kumar, Vinod and Woodruff, Trent M. (2016). Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. Human Molecular Genetics, 25 (9) ddw050, 1780-1791. doi: 10.1093/hmg/ddw050

A Bifunctional Role for Group IIA Secreted Phospholipase A(2) in Human Rheumatoid Fibroblast-like Synoviocyte Arachidonic Acid Metabolism

Bryant, Katherine J., Bidgood, Matthew J., Lei, Pei-Wen, Taberner, Megan, Salom, Caroline, Kumar, Vinod, Lee, Lawrence, Church, W. Bret, Courtenay, Brett, Smart, Brian P., Gelb, Michael H., Cahill, Michael A., Graham, Garry G., McNeil, H. Patrick and Scott, Kieran F. (2011). A Bifunctional Role for Group IIA Secreted Phospholipase A(2) in Human Rheumatoid Fibroblast-like Synoviocyte Arachidonic Acid Metabolism. Journal of Biological Chemistry, 286 (4), 2492-2503. doi: 10.1074/jbc.M110.123927

Stimulating the Activity of NEP and ACE2: A Unique Approach to Prevent Dementia

Tran, Shirley, Woodruff, Trent, Kumar, Vinod, Smith, A. Ian, Rajapakse, Niwanthi and Kuruppu, Sanjaya (2021). Stimulating the Activity of NEP and ACE2: A Unique Approach to Prevent Dementia. Experimental Biology Meeting EB 2021, Online, 27–30 April 2022. Hoboken, NJ United States: John Wiley & Sons. doi: 10.1096/fasebj.2021.35.s1.01628

Complement C5a activates microglial NLRP3 inflammasomes and drives neurodegeneration in Parkinson's disease through C5aR1

Gordon, Richard, Albornoz, Eduardo A., Kumar, Vinod, Zhou, Kiane, Garin-Michaud, Ashoka, Mantavani, Susanna, Kanthasamy, Anumantha G. and Woodruff, Trent M. (2016). Complement C5a activates microglial NLRP3 inflammasomes and drives neurodegeneration in Parkinson's disease through C5aR1. The XXVI International Complement Workshop (ICW), Kanazawa, Japan, 4-8 September 2016. Muenchen, Germany: Elsevier. doi: 10.1016/j.imbio.2016.06.146

Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration

Kumar, Vinod, Lee, John, Noakes, Peter and Woodruff, Trent (2015). Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration. 8th International Conference on Complement Therapeutics, Chania, Crete, Greece, 1-6 January 2015.

Behavioural and pathological phenotyping of the C57BL/6J BACHD transgenic mouse model of Huntington’s disease

Mantovani, S., Li, R., Gordon, R., Kumar, V., Taylor, S. and Woodruff, T. M. (2013). Behavioural and pathological phenotyping of the C57BL/6J BACHD transgenic mouse model of Huntington’s disease. World Congress on Huntington’s disease, Rio de Janeiro, Brazil, 15-18 September 2013. Amsterdam, Netherlands: I O S Press.

Pharmacokinetics of complement C5a receptor 1 antagonists in mice, and their role in protecting CNS barriers during neurodegeneration

Kumar, Vinod (2017). Pharmacokinetics of complement C5a receptor 1 antagonists in mice, and their role in protecting CNS barriers during neurodegeneration. PhD Thesis, Medicine Faculty, The University of Queensland. doi: 10.14264/uql.2017.471